The company will exhibit at Booth 236028 from September 14 to 19 at McCormick Place, Chicago, showcasing components produced by its HIP customers

CHICAGO, Sept. 8, 2026 /PRNewswire/ -- Hiperbaric will present its range of Hot Isostatic Pressing (HIP) equipment at the International Manufacturing Technology Show (IMTS) 2026, held September 14 to 19 at McCormick Place in Chicago. The company will be at Booth 236028 in the North Building, Level 3, where it will display sample components produced by HIP customers and meet with manufacturers evaluating the process for cast and additively manufactured parts.

HIP applies high pressure and high temperature to a component at the same time, closing the internal porosity and micro-defects left by casting and by powder-bed additive processes. Hiperbaric's presses operate at pressures up to 207 MPa (30,000 psi), with maximum temperature set by furnace type: 2,000 °C (3,632 °F) with a graphite furnace and 1,400 °C (2,552 °F) with molybdenum. Metallic parts leave the cycle at full theoretical density, with measurable gains in fatigue life, ductility, and impact strength. Some ceramic components can retain minor residual porosity. For additively manufactured parts, HIP is the step that brings mechanical performance in line with forged material.

"The North American market leads in additive manufacturing adoption, but industrializing these processes means proving structural reliability in the parts that carry load," said Andrés Hernando, CEO of Hiperbaric. "Our presence at IMTS 2026 reflects a long-term commitment to US manufacturers. We bring the process expertise that aerospace and medical producers need to qualify parts, alongside the equipment itself."

A HIP Range from Materials Qualification to Serial Production

Hiperbaric builds HIP systems across a range of hot zone sizes. The HIP 38 offers a 380 mm (14.96 in) hot zone diameter and 850 mm (33.46 in) usable height. Its size and performance make it suitable for installation in companies with medium production capacities. The HIP 107 offers a 1,075 mm (42.3 in) diameter and 2,670 mm (105.1 in) height for serial production runs. Both operate at 207 MPa (30,000 psi) and reach 1,400 °C with a molybdenum furnace or 2,000 °C with graphite.

Across the range, the presses share a control architecture built to hold cycle parameters repeatable from first qualification runs through production, and a vessel and furnace design aimed at reducing energy consumption per cycle. Specialists from the company's HIP team will walk visitors through configurations, cycle times, and installation requirements at the booth.

Applications and Qualification

Aerospace manufacturers apply HIP to nickel superalloys, titanium alloys, and other high-performance alloys used in engine components and structures. Medical manufacturers use it on implants and prosthetics, where density and fatigue behavior govern service life. Further applications include gas turbine components for the energy sector, high-load automotive parts, and tooling and dies, where HIP extends time between replacements. Components representing several of these applications will be shown at the stand.

Producers qualifying HIP as a heat treatment operation work under AMS 2750 pyrometry requirements and, for aerospace supply chains, Nadcap AC7102/6 audit criteria. Hiperbaric designs the instrumentation, temperature uniformity, and control systems on its HIP equipment to support customers working toward those requirements.

Hiperbaric also builds Cold Isostatic Pressing (CIP) equipment. CIP applies uniform hydrostatic pressure at room temperature, from 100 to 600 MPa (14,500 to 87,000 psi), compacting metallic or ceramic powders in an elastomeric mold into near-net-shape green parts at up to 95% of theoretical density before sintering.

Manufacturers and partners can book a technical or commercial meeting with Hiperbaric's HIP specialists during the show by writing to [email protected]. Media inquiries should be directed to the contact below.

About Hiperbaric

Founded in 1999, Hiperbaric designs, manufactures, and markets industrial high-pressure equipment. The company operates subsidiaries in the United States, Asia, and Oceania, with hundreds of systems installed across five continents. Its technology lines are High Pressure Processing (HPP) for food and beverage, Hot Isostatic Pressing (HIP) for advanced manufacturing, and green hydrogen (H2) compression systems. Hiperbaric's integrated management system for high-pressure equipment is certified to ISO 9001, ISO 14001, and ISO 45001.

For more information, visit www.hiperbaric.com.

Download media kit here: https://we.tl/t-CPBESmTpzXHm2S2M

Media Contact

Hiperbaric Communication and Marketing Department

Cristina Pérez Villegas

[email protected] | www.hiperbaric.com

SOURCE Hiperbaric

Share this article

University of Illinois Springfield and Non-Profit Ed3 Global Partner to Help Illinois K-12 Educators Put AI Guidance Into Practice

Following Illinois' release of comprehensive statewide AI guidance for schools, UIS and ION eLearning partner with Ed3 to translate policy into classroom-ready professional learning

SPRINGFIELD, Ill., Sept. 8, 2026 /PRNewswire/ -- The University of Illinois Springfield (UIS), through its Center for Academic and Professional Education (CAPE) and ION eLearning program, and Ed3 have announced a strategic partnership to deliver AI literacy and professional development courses designed for educators across Illinois. The partnership positions UIS among institutions working to translate emerging state-level AI guidance into scalable, credit-bearing professional learning for teachers.

On July 9, 2026, the Illinois State Board of Education (ISBE) released comprehensive statewide guidance on the use of artificial intelligence in PreK-12 schools. For districts across Illinois, the challenge now is translating that guidance into classroom practice. UIS's ION eLearning brings more than 25 years of experience delivering professional development in online teaching, online leadership, accessibility, and open educational resources. Through the partnership, UIS is pairing that infrastructure with Ed3's classroom-tested, pedagogy-first approach to AI professional learning, creating a ready-made pathway for Illinois educators to move from AI guidance to implementation.

Starting September 8, 2026, UIS will offer a suite of self-paced, fully online courses and stackable micro-credentials co-developed with Ed3, a nonprofit that has supported more than 20,000 educator enrollments across 48 states, representing more than 900,000 hours of professional development. Rather than treating AI as a tool to bolt onto existing practice, the courses begin with research-based pedagogy and build outward, equipping educators with the judgment and practical skills to use AI thoughtfully to strengthen teaching and learning.

"The University of Illinois Springfield and ION eLearning are proud to partner with Ed3 to expand access to high-quality pedagogy-first AI professional learning for teachers across Illinois."

~ Russ Stoup, Acting Director of Continuing and Professional Education, University of Illinois Springfield

"PreK-12 AI guidance is only as good as the degree to which it positively impacts instruction in the classroom. What stands out about this partnership is that UIS and ION eLearning aren't waiting to see how the policy-to-practice gap gets closed - they're taking the lead on it, giving Illinois teachers a credentialed, classroom-ready way to put this guidance into practice right now. That's the kind of leadership we think every state needs from its higher-ed partners, and we're proud to help UIS deliver it."

~ Vriti Saraf, Founder & CEO, Ed3

Courses are available for Professional Development Hours (PDHs) and Continuing Education Units (CEUs), with stackable micro-credential pathways that allow educators to build credentials over time and move from AI literacy to AI agency.

For more information or to enroll, visit https://www.uis.edu/cape/ed3-ai-training or contact [email protected].

About the University of Illinois Springfield

The University of Illinois Springfield is a public university and member of the University of Illinois System. Through its Center for Academic and Professional Education (CAPE) and ION eLearning program, UIS has provided professional development for educators in online teaching, online leadership, accessibility, and open education resources since 1999, serving education professionals across Illinois and beyond.

About Ed3

Ed3 is a 501(c)(3) nonprofit preparing educators for the age of AI through professional learning, research and development, and a global community of practice. Its pedagogy-first approach to AI professional development helps educators use emerging technology to strengthen teaching and learning. Through university and professional learning partners, Ed3 has supported more than 20,000 educator enrollments across 48 states, representing more than 900,000 hours of professional development. Ed3 also leads The Portrait of a Teacher in the Age of AI, a national research and development initiative exploring how the role of the teacher must evolve in a world transformed by AI.

Media Contact

Everett Reiss, Ed3, [email protected], 646.926.2424

SOURCE Ed3 Global

Share this article

Geotab-Studie zeigt: Lkw sind in Berlin effizienter unterwegs als Pkw

Lkws in Berlin erreichen bei der Verkehrseffizienz 16 Punkte mehr als Pkw. Europaweit schneiden Lkw in fünf von sieben untersuchten Hauptstädten besser ab.

AACHEN, Deutschland, 8. September 2026 /PRNewswire/ -- Lkw sind im Berliner Stadtverkehr effizienter unterwegs als Pkw. Das zeigt der Index für die Frachteffizienz in Städten Europas* von Geotab, Anbieter vernetzter Transportlösungen. Der Index bewertet für jede Stadt separat auf einer Skala von 0 bis 100 Punkten, wie effizient sich Lkw und Pkw im Straßenverkehr bewegen. Dabei wird beispielsweise berücksichtigt, wie flüssig der Verkehr läuft oder wie viel Kraftstoff durch Leerlauf verbraucht wird. Die Analyse basiert auf dem Gesamtjahr 2025 und Daten von Geotab-vernetzten Fahrzeuge in Berlin, Amsterdam, Dublin, Rom, Paris, London und Madrid.

Die Ergebnisse stellen eine verbreitete Annahme infrage: Lkw sind nicht grundsätzlich die größere Belastung für die Effizienz des Stadtverkehrs. In vielen Städten profitieren Flotten von professioneller Routenplanung und der Möglichkeit, Stoßzeiten zu vermeiden. Dort, wo Lkw schlechter abschneiden als Pkw, scheinen dagegen strukturelle Faktoren des Straßennetzes und der Verkehrsregulierung eine größere Rolle zu spielen.

Europaweit sind Lkw in fünf der sieben untersuchten Hauptstädte effizienter unterwegs als Pkw. Rom verzeichnet mit 26 Punkten den größten Effizienzvorsprung der Lkw gegenüber Pkw, gefolgt von Berlin mit 16 Punkten. Auch in Dublin und Amsterdam schneiden Lkw zweistellig besser ab, während sie in Paris trotz der höchsten Leerlaufquote noch vor den Pkw liegen. Lediglich in London und Madrid sind Pkw effizienter unterwegs – wobei die Gründe unterschiedlich sind: In London dürften unter anderem verkehrspolitische Vorgaben den Wirtschaftsverkehr bremsen, während Madrid durch besonders schwierige und wenig planbare Verkehrsbedingungen für Lkw geprägt ist.

Berlin: Gute Voraussetzungen für planbare Lieferungen

Berlin erreicht mit einem Lkw-Wert von 71 den höchsten Wert der sieben untersuchten Städte. Pkw kommen auf 55 Punkte. Der Abstand von 16 Punkten zugunsten der Lkw lässt sich unter anderem mit der vergleichsweise weitläufigen Straßeninfrastruktur und der polyzentrischen Struktur Berlins erklären. Anders als Städte mit nur einem dominanten Zentrum verteilt sich der Verkehr auf mehrere Bereiche Dadurch kommt es seltener zu starken Verkehrsspitzen während der Stoßzeiten.

Für Liefer- und Dienstleistungsflotten bedeutet das vor allem bessere Planbarkeit des täglichen Betriebs. Der Wert für die Zuverlässigkeit der Fahrzeiten schwankt nur gering zwischen 95 und 100 Punkten. Mithilfe historischer Daten können Flottenbetreiber die Fahrzeiten und Lieferungen damit zuverlässiger planen. Auf den Leerlauf von Lkw entfallen in Berlin 8,5 Prozent des gesamten Kraftstoffverbrauchs, verglichen mit 13,2 Prozent bei Pkw.

Paris: Lkw effizienter trotz hohem Leerlauf

In Paris zeigt, zeichnet sich ein Bild ab, das zunächst widersprüchlich erscheint. Zwar weisen Lkw dort mit 18,2 Prozent die höchste Leerlaufquote aller untersuchten Städte auf. Trotzdem erreichen sie beim Gesamteffizienzwert 46 Punkte und liegen damit deutlich vor den Pkw mit 31 Punkten. Ein möglicher Grund dafür könnte sein, dass Lkw bestimmte Verkehrsbedingungen leichter umgehen können. In Paris gibt es für den Pkw-Verkehr kein Zeitfenster, in dem die Verkehrsbelastung unter den kritischen Schwellenwert fällt. Durch professionelle Routenplanung und die Nutzung von Zeitfenstern außerhalb der stärksten Verkehrsspitzen können Flotten diese Belastung teilweise umgehen.

London: Strukturelle Faktoren beeinträchtigen den Lkw-Verkehr

London bildet einen der beiden Ausnahmen im Städtevergleich. Hier schneiden Pkw mit 29 Punkten knapp besser ab als Lkw mit 27 Punkten. Die Daten deuten darauf hin, dass strukturelle Rahmenbedingungen den Wirtschaftsverkehr besonders stark beeinflussen. Dazu zählen etwa umfangreiche Busspurregelungen, die Lkw nicht nutzen können, engere Straßen in der Nähe der Innenstadt oder Umweltzonen. Hinzu kommen komplexe Vorgaben für Be- und Entladevorgänge, die Lieferungen in ungünstige Zeitfenster drängen.

Beim Kraftstoffverbrauch weisen Lkw in London mit 36,75 Litern pro 100 Kilometer den höchsten Verbrauch aller untersuchten Städte auf. Die Leerlaufquote liegt bei 11,1 Prozent des gesamten Kraftstoffverbrauchs – zwar unter dem Wert der Pkw von 13,6 Prozent, aber deutlich über den entsprechenden Werten für Lkw in Berlin, Rom oder Dublin.

Professionelles Flottenmanagement macht den Unterschied

Der Vergleich der sieben Städte zeigt, dass die Effizienz des Wirtschaftsverkehrs nicht allein von der Fahrzeugart abhängt. Wo Flottenbetreiber ihre Fahrten flexibel planen, Routen optimieren und verkehrsärmere Zeitfenster nutzen können, können Lkw gegenüber dem allgemeinen Pkw-Verkehr sogar im Vorteil sein. Bleibt dieser aus, liegen die Ursachen jedoch nicht zwingend im Flottenmanagement selbst. Infrastruktur, Verkehrsregeln und die Verteilung von Lieferzeitfenstern können die Möglichkeiten erheblich einschränken. Für Flottenmanager liefert der Index damit nicht nur Hinweise darauf, wo sich der eigene Betrieb optimieren lässt, sondern auch darauf, wo strukturelle Rahmenbedingungen die Effizienz begrenzen.

„Die Annahme, dass Lkw grundsätzlich die Hauptverursacher eines ineffizienten Verkehrs in Städten sind, wird durch unsere Daten nicht bestätigt", so Fabian Seithel, AVP EMEA bei Geotab. „In den meisten untersuchten europäischen Städten sind professionelle Flotten effizienter unterwegs als der Pkws. Dazu tragen unter anderem eine strukturierte Routenplanung, bessere Zeitpläne und datenbasierte Entscheidungen bei. Für Flottenbetreiber gilt dabei: Je genauer sie wissen, wo Kosten und Ineffizienzen entstehen, desto gezielter können sie gegensteuern."

Den vollständigen Bericht lesen Sie hier.

*Methodik

Der Index für die Frachteffizienz in Städten Europas bewertet die Verkehrseffizienz in sieben europäischen Städten auf einer Skala von 0 bis 100. Lkw und Pkw werden dabei jeweils separat betrachtet. Der Gesamtindex der Städte wird anschließend mit einer Gewichtung von 60 Prozent für Pkw und 40 Prozent für Lkw berechnet. Damit wird berücksichtigt, dass Pkw den größeren Anteil des Verkehrsaufkommens ausmachen, während die Lkw-Daten gezielt Aufschluss über die Effizienz des Wirtschaftsverkehrs geben.

Der jeweilige Fahrzeugwert setzt sich aus zwei Dimensionen zusammen. 75 Prozent entfallen darauf, wie sich der Verkehr bewegt. Dabei werden die tägliche Verkehrsbelastung (50 Prozent), die Anzahl der Stunden mit flüssigem Verkehr (25 Prozent) und die Schwankung der Fahrzeiten berücksichtigt (25 Prozent). Die verbleibenden 25 Prozent messen die Kosten der Verkehrsbelastung anhand des Leerlaufs während der Fahrt. Eine höhere Leerlaufquote deutet dabei unter anderem auf Verkehrsstaus, ungünstige Ampelschaltungen und Engpässe hin.

Die Auswertung basiert auf Daten aus dem gesamten Jahr 2025 (Januar bis Dezember) von Geotabs Plattform für vernetzte Fahrzeuge in Berlin, Amsterdam, Dublin, Rom, Paris, London und Madrid. Die Werte sind normalisierte relative Vergleichswerte auf Basis einer Stichprobe vernetzter Fahrzeuge und stellen keine Vollerhebung des gesamten Fahrzeugbestands dar.

Über Geotab

Geotab ist ein weltweit führender Anbieter von Lösungen für vernetzte Fahrzeuge und Asset-Management mit Hauptsitzen in Oakville, Ontario, und Atlanta, Georgia USA. Unsere Mission ist es, die Welt sicherer, effizienter und nachhaltiger zu machen. Wir nutzen fortschrittliche Datenanalysen und KI, um die Leistung und den Betrieb von Fuhrparks zu transformieren, Kosten zu senken und Effizienz zu steigern. Unterstützt von führenden Expertinnen und Experten aus den Bereichen Datenwissenschaft und Ingenieurwesen bedienen wir rund 100.000 Kundinnen und Kunden weltweit und verarbeiten täglich 100 Milliarden Datenpunkte von mehr als 5 Millionen Fahrzeugen. Fortune-500-Unternehmen, mittelständische Fuhrparks und die größten Flotten des öffentlichen Sektors der Welt, einschließlich der US-Bundesregierung, vertrauen auf Geotab. Wir verpflichten uns der Datensicherheit und dem Datenschutz und verfügen über FIPS 140-3- und FedRAMP-Zulassungen. Unsere offene Plattform, unser Ökosystem aus herausragenden Partnern und der Geotab Marketplace bieten Hunderte von fuhrparkfertigen Lösungen von Drittanbietern. Dieses Jahr feiern wir 25 Jahre Innovation. Erfahren Sie mehr unter www.geotab.com/de, folgen Sie uns auf LinkedIn oder besuchen Sie unseren Blog.

GEOTAB und GEOTAB MARKETPLACE sind eingetragene Warenzeichen von Geotab Inc. in Kanada, den Vereinigten Staaten und/oder anderen Ländern.

Pressekontakt: Hotwire für Geotab, Charlotte Duda, +49 171 422 3715, [email protected]

Share this article

Resident insurance compliance management, affordable liability coverage, and a new line of revenue for the community

AUSTIN, Texas, Sept. 8, 2026 /PRNewswire/ -- SafeLease, a technology-driven insurance provider serving more than 4,000 commercial properties, today announced the launch of SafeHome, its suite of insurance products for manufactured housing community operators.

Nearly every manufactured housing lease requires residents to carry liability coverage, but property management systems do not track compliance, and an estimated 35% of manufactured homeowners carry no insurance at all.1 When an uninsured resident has a loss, the claim frequently lands on the community owner.

SafeHome provides:

- Verification. SafeHome makes it easy for residents to provide evidence of their own policy or enrolls them in coverage. Communities can easily verify that 100% of their residents are compliant with insurance requirements.

- Coverage residents can afford. The SafeHome liability waiver carries limits from $100,000 to $500,000, starting at $20 per month, reaching residents priced out of full homeowner's coverage.

- A compliance dashboard. Coverage status for every home in one shared view, with no separate system for site staff to learn. SafeHome integrates with leading manufactured housing management software.

- Revenue on every enrolled home. Communities earn a monthly admin fee for each home enrolled in coverage. A community can model its own numbers with the NOI calculator at safelease.com/safehome.

"Across commercial real estate, SafeLease's role is to reduce property managers' risk while providing an ancillary revenue source," said Kierstin Payne, Director of Manufactured Housing Sales at SafeLease. "Helping managers administer their lease requirements is where that starts. In manufactured housing the coverage clause is already in nearly every lease. What has been missing is an easy way to track compliance and offer affordable coverage for residents."

SafeHome will be available to manufactured housing community operators nationwide.

To learn more, visit safelease.com/safehome.

About SafeLease

SafeLease is a technology and insurance provider for commercial real estate owners, serving more than 4,000 commercial properties. SafeLease's automation-driven approach to implementing and managing revenue-driving programs has generated over $1 billion in enterprise value for property owners. Learn more at safelease.com.

1 Consumer Federation of America, "EXPOSED: A Report on 1.6 Trillion Dollars of Uninsured American Homes," March 2024.

SOURCE SafeLease

Share this article

Announced by CPT Group, Inc.

IRVINE, Calif., Sept. 8, 2026 /PRNewswire/ -- CPT Group, Inc., announces a proposed Settlement in a class action lawsuit called Bates, et al., v. Wayne Memorial Hospital Auxiliary, Inc. d/b/a Wayne Memorial Hospital, Case No. SUCV2025000239, In the Superior Court of Wayne County State of Georgia (the "Action").

What is this about? The Action is related to an incident discovered on or around June 3, 2024 (the "Data Incident"). Wayne Memorial Hospital Auxiliary, Inc. d/b/a Wayne Memorial Hospital ("Defendant") determined that certain files may have been accessed without authorization between approximately May 30, 2024 to June 3, 2024, and, on or around August 27, 2025, sent out notices to potentially impacted individuals. The Action alleges that Defendant was negligent or otherwise responsible for failing to prevent the Data Incident from occurring. Defendant denies all allegations.

Who is affected? You are a Settlement Class Member if your Private Information was accessible because of the Data Incident which was discovered on or around June 3, 2024.

What does the Settlement provide? The Settlement provides monetary relief. Settlement Class Members may submit a Claim for a cash payment. All Settlement Class Members are also eligible to enroll in Credit Monitoring Services.

How do I file a claim? Claim Forms are available for download and online submission at www.WMHDataSettlement.com. The deadline to submit a Claim Form, either online or via email or U.S. Mail, is December 7, 2026.

What are my other options? You can do nothing, exclude yourself, or object to the Settlement.

Do Nothing: If you do nothing, you will not receive a credit monitoring enrollment code or a cash payment. You will remain a member of the Settlement Class, be bound by the Settlement if it is approved by the Court, and give up the right to sue Defendant over the claims resolved by the Settlement.

Exclude Yourself: If you exclude yourself, you will not be able to enroll in credit monitoring or receive a cash payment, but you may be able to file your own lawsuit against Defendant, for the same claims. This is the only option that leaves you the potential to file your own lawsuit against Defendant for the claims that are being resolved by the Settlement. To be effective, you must submit a request for exclusion by the deadline by November 7, 2026.

Object: If you do not exclude yourself from the Settlement Class, you may submit an objection, by November 7, 2026, telling the Court why you do not like the Settlement. If your objection is overruled, you will be bound by the Settlement.

What happens next? The Court will hold a Final Approval Hearing on January 27, 2027 at 1:30 p.m. ET at the Superior Court of Wayne County, State of Georgia to consider final approval of the Settlement, payment of attorneys' fees, costs, and expenses and the Plaintiffs' service awards. You may attend the hearing at your own expense, or you may pay your own lawyer to attend, but it is not necessary.

How do I get more information? For more information and to view the full notice, Claim Form, a copy of the Settlement Agreement, and other documents, go to www.WMHDataSettlement.com. You may also contact the Settlement Administrator toll-free at 1-888-716-0934, by email at [email protected] or by writing to Wayne Memorial Data Incident, c/o CPT Group, Inc., PO Box 19504, Irvine, CA 92623.

PLEASE DO NOT CONTACT THE COURT OR THE COURT CLERK'S OFFICE

SOURCE CPT Group, Inc.

Share this article

Kommentar von "nd.DerTag" zur Reform der Notfallversorgung

Berlin (ots)

Die Bundesregierung will die Notfallversorgung vor allem dadurch reformieren, dass sie die Patienten stärker steuert. Das ist verständlich, solange noch Menschen mit einer Zecke am Körper oder mit bereits seit drei Wochen dauernden Beinschmerzen die 112 wählen. Andererseits stimmt hier generell etwas nicht. Und das hat nicht nur mit fehlenden Gesundheitskompetenzen in der Bevölkerung zu tun.

In einer Umfrage hat die Linke-Bundestagsfraktion Rettungskräfte auch dazu befragt, was aus ihrer Sicht die häufigsten Gründe für Fehleinsätze sind. An erster Stelle kommt hier die fehlende Kenntnis von anderen Angeboten, in mehr als 40 Prozent der Antworten. Die Leute wissen also nicht, dass sie es erst einmal beim Hausarzt versuchen sollten - manchmal hilft sogar die Apotheke. Aber der Hausarzt in der Nähe nimmt keine neuen Patienten an, die Apotheke hat gerade zugemacht. Das Krankenhaus ist zu weit weg. Gespart wird überall, und nach dem Willen der Bundesregierung soll noch viel mehr gespart werden.

Am Ende werden aus vielen eingesparten Strukturen echte Notfälle, deutlich über eine Zecke oder Beinschmerzen hinaus. Am Ende rufen die Leute dann die Feuerwehr. In die Notaufnahmen kommen jetzt schon Menschen in psychischen Krisen (immer wieder), Wohnungslose, Suchtpatienten, Familien in größten Ängsten. Die Rettungsdienste fahren im Wortsinn pausenlos. Die Wege zu den Kliniken sollen in Zukunft noch länger werden. Und so hieß es von Rettungskräften in der erwähnten Umfrage: "Schließen Sie nicht noch mehr Krankenhäuser!" Zu befürchten ist aber, dass genau das passiert, da diese Regierung als Letztes die Beschäftigten vor Ort fragen wird. Und die Patienten schon gar nicht.

Pressekontakt:

nd.DerTag / nd.DieWoche

Redaktion

Telefon: 030/2978-1722

Original-Content von: nd.DerTag / nd.DieWoche, übermittelt durch news aktuell

rbb - Rundfunk Berlin-Brandenburg

Berliner Linken-Spitzenkandidatin: Vergesellschaftung braucht Zeit

Berlin (ots)

Die Spitzenkandidatin der Linken für die Berliner Abgeordnetenhauswahl, Elif Eralp, hat eingeräumt, dass die Vergesellschaftung großer Immobilienkonzerne nicht umgehend möglich sei. Das brauche Zeit, sagte Eralp dem rbb.

Um die Mieten in Berlin zu senken, sprach sich Eralp für eine Vergesellschaftung großer Immobilienkonzerne mit mehr als 3.000 Wohnungen aus. Sie wolle die Mietpreise dadurch beeinflussen, dass mehr Wohnungen der Stadt gehören. Zudem wolle die Linke beispielsweise einen Mietendeckel für landeseigene Wohnungsbaugesellschaften sowie ein Landesamt für Mieterschutz.

Ein weiteres zentrales Thema: Antisemitismus müsse sofort bekämpft werden, sagte Eralp auf rbb-Nachfrage. Sie nehme die Sorgen der jüdischen Gemeinde sehr ernst, so Eralp. Von dem Auftritt eines Rappers auf einer Veranstaltung der Linken in Neukölln, der unter anderem in einer Textzeile die Vernichtung der israelischen Armee gefordert hatte, habe sie sich bereits distanziert. Ihre Landesvorsitzende, Kerstin Wolter, und sie hätten den Vorfall verurteilt. Er werde in den Parteigremien weiter aufgearbeitet. Eine Nachfrage zu personellen Konsequenzen nach dem Vorfall ließ Eralp offen, ebenso zu den eingeleiteten staatsanwaltschaftlichen Ermittlungen. Sie sei darüber nicht informiert und das sei Sache der Behörden. Eralp sagte, sie stehe für den Schutz jüdischen, genauso wie muslimischen und palästinensischen Lebens in der Stadt. Sie wolle zusammenführen.

Mit Blick auf den Landeshaushalt sprach Eralp sich gegen eine Olympia-Bewerbung der Stadt aus. Das sei Geldverschwendung. Um höhere Einnahmen für das Landes zu erzielen, will sie unter anderem die Grunderwerbssteuer erhöhen.

Pressekontakt:

Rundfunk Berlin-Brandenburg

Landespolitik Berlin

Chefin/Chef vom Dienst

Tel.: 030 - 979 93-70 250

Mail: lapo-berlin@rbb-online.de

Original-Content von: rbb - Rundfunk Berlin-Brandenburg, übermittelt durch news aktuell

Captain's Circle Elite Members Can Enter Through September 22

FORT LAUDERDALE, Fla., Sept. 8, 2026 /PRNewswire/ -- Princess Cruises is inviting Princess Captain's Circle Elite members to enter the "Share Your Princess Story" contest for a chance to ride aboard the cruise line's floral float in the 138th Rose Parade® presented by Honda on January 1, 2027, in Pasadena, Calif. Four winners will each receive a trip for two and the opportunity to "sail" down Colorado Boulevard on Princess' float; entries are open now through September 22, 2026.

"Princess guests have been at the heart of our story for more than 60 years, and many have shared incredible moments with us across decades of travel," said Marie Lee, Princess Cruises Chief Marketing Officer. "As we celebrate the Rose Parade theme of 'Welcome,' we can't think of a more meaningful way to bring it to life than by inviting some of our most loyal guests to share the Princess stories they treasure most - and welcoming four of them aboard our float on New Year's Day."

How to Enter

To enter, eligible Captain's Circle Elite members can submit a 300- to 500-word essay that celebrates the unforgettable memories, meaningful connections, and extraordinary destinations that have made Princess part of their story. The entry form, official rules, prize description and eligibility details are available at www.princessshareyourstory.com and terms and conditions apply.

The contest is open to legal residents of the 50 United States and the District of Columbia, and Canada (excluding Quebec) who are at least 18 years old at the time of entry and have completed 15 cruises, or 150 cruise days, with Princess Cruises as of the start of the contest.

Four winners will be selected by October 6. Each will receive a trip for two to Pasadena, Calif., including the opportunity for the winner to ride aboard the Princess Cruises float in the 2027 Rose Parade® on New Year's Day.

Every Princess Guest Has a Story

For more than 60 years, Princess has welcomed millions of guests aboard its ships, creating memories across extraordinary destinations around the world. From milestone celebrations and multigenerational vacations to friendships, love stories and unforgettable moments ashore, the contest invites guests to share the experiences that made Princess part of their story.

A Float Inspired by Welcome, Discovery and Connection

Princess Cruises recently announced its return to the Rose Parade for a second consecutive year with "Welcome Aboard – Find Your Story," a destination-inspired float celebrating the 2027 Pasadena Tournament of Roses® theme, "Welcome." The float reflects the discovery, connection and sense of belonging that comes with exploring the world.

Designed and built by Artistic Entertainment Services, the Princess float will measure approximately 55 feet long and 22 feet high and feature more than 320,000 flowers, seeds, bark, leaves and other natural materials. Through rich floral textures, vibrant colors and animation, the float will showcase Princess destinations including Alaska, Japan, Australia and Europe.

The Rose Parade draws approximately 800,000 spectators along Colorado Boulevard in Pasadena and more than 28 million U.S. television viewers, with millions more watching around the world.

Additional information about Princess Cruises is available through a professional travel advisor, by calling 1-800-PRINCESS (1-800-774-6237), or by visiting princess.com.

About Princess Cruises:

Princess Cruises is The Love Boat, the world's most iconic cruise brand that delivers dream vacations to millions of guests every year in the most sought-after destinations, on the largest ships offering the personalized service and simplicity of small, yacht-class ships. Well-appointed staterooms, world-class dining, grand performances, award-winning casinos and entertainment, luxurious spas, imaginative experiences and boundless activities blend with exclusive Princess MedallionClass service to create meaningful connections and unforgettable moments in the most incredible settings in the world — the Caribbean, Alaska, Panama Canal, Mexican Riviera, Europe, South America, Australia/New Zealand, the South Pacific, Hawaii, Asia, Canada/New England, Antarctica, and World Cruises. Star Princess, the brand's newest and most innovative ship, launched in October 2025 and is sister ship to Sun Princess, named Condé Nast Traveler Mega Ship of the Year for a second consecutive year. The company is part of Carnival Corporation, the world's largest cruise company with a portfolio of cruise lines operating in more than 800 ports and destinations worldwide (NYSE: CCL).

SOURCE Princess Cruises

Share this article

30-day ocean voyage on Seabourn Quest sails roundtrip from Miami with scenic Amazon River cruising, visits to river communities and an overnight stay in Manaus

Key Points

- Seabourn has announced a new 30-day "Amazon Explorer: Rivers & Rainforests" voyage aboard Seabourn Quest, sailing roundtrip from Miami from Nov. 18 to Dec. 18, 2028.

- The voyage visits 15 destinations across seven countries, combining Caribbean islands, scenic Amazon River cruising and visits to destinations along the Amazon River, including Santarém, Boca da Valeria, Parintins, Manaus and more.

- Guests will enjoy an overnight stay in Manaus, providing additional time to explore one of the Amazon's most culturally rich destinations.

- Sailing during Seabourn's Ruby Jubilee year, the voyage is part of the line's 40th anniversary celebration in 2028.

SEATTLE, Sept. 8, 2026 /PRNewswire/ -- Seabourn has announced a new 30-day "Amazon Explorer: Rivers & Rainforests" voyage on Seabourn Quest, inviting guests to experience one of the world's most remarkable waterways through a journey that combines scenic Amazon River cruising, riverside destinations and an overnight stay in Manaus. Sailing roundtrip from Miami from Nov. 18 to Dec. 18, 2028, the luxury ocean voyage visits 15 destinations across seven countries and is part of Seabourn's Ruby Jubilee year celebrating the line's 40th anniversary.

As luxury travelers increasingly seek deeper, more authentic experiences and opportunities to explore more culturally rich destinations, Seabourn's new Amazon voyage offers a distinctive way to discover one of the world's most fascinating regions. Stretching across northern South America, the Amazon is home to extraordinary biodiversity, the world's largest rainforest and one of its most iconic waterways. The new voyage follows a thoughtfully designed route from the Caribbean into the Amazon River, offering guests opportunities to experience vibrant cultures, remote communities and the changing landscapes that have captivated explorers and travelers for generations.

"The Amazon is one of the world's most fascinating destinations, offering a sense of exploration unlike anywhere else in the world," said Mark Tamis, President of Seabourn. "Seabourn Quest will take guests into the heart of the Amazon to discover its extraordinary landscapes, cultures and traditions, while delivering the personalized service, thoughtfully curated experiences and intimate atmosphere that define Seabourn."

The voyage also kicks off a season of extended travel aboard Seabourn Quest. Following the Amazon sailing, the ship will embark on two 10-day Caribbean holiday voyages before departing Miami on Jan. 7, 2029, for its 138-day World Cruise: Iconic Islands & Remote Horizons, giving guests additional opportunities to extend their time on board, travel farther and explore some of the world's most extraordinary regions more deeply.

Exploring River, Rainforest and Local Cultures

The voyage begins in Miami and winds through the Caribbean before entering the Amazon River, creating a natural progression from island destinations to one of the world's great waterways. Throughout the voyage, guests will experience the Amazon through scenic cruising and visits to destinations that reveal life along the river.

A highlight of the voyage is the overnight stay in Manaus, a historic city surrounded by rainforest and long regarded as a gateway to the Amazon. The extended stay provides guests with more time to experience the city's architecture, markets, cultural landmarks and vibrant waterfront.

Stops at Santarém, Boca da Valeria and Parintins offer opportunities to experience the landscapes, cultures and traditions shaped by one of the world's great waterways. The ship will visit Devil's Island in French Guiana, known for its dramatic history and remote setting, as well as calls in the Caribbean, including Saint Barthelemy, Trinidad and Grenada, adding further depth to the journey.

Featured Voyage Highlights

- Amazon River Scenic Cruising - Sail along one of the world's most legendary waterways, taking in rainforest landscapes and river life.

- Manaus, Brazil - Enjoy an overnight stay in the gateway to one of most captivating cities in the Amazon, with more time to explore the city's culture, colorful markets, and acclaimed restaurants showcasing local flavors.

- Santarém, Brazil - Discover a destination near the confluence of the Amazon and Tapajós rivers, where the sediment-rich brown waters of the Amazon flow alongside the clear blue-green waters of the Tapajós before gradually blending together.

- Boca da Valeria, Brazil - Visit a small riverside community surrounded by dense rainforest, offering a rare glimpse at the everyday life along the Amazon.

- Parintins, Brazil - Experience one of the Amazon's most vibrant river destinations.

- Devil's Island, French Guiana - Explore a destination known for its dramatic history and remote setting.

- Gustavia, Saint Barthelemy - Set around a yacht-like harbor rarely accessible to larger ships, this hidden, elegant harbor blends Swedish colonial and French Creole architecture with chic boutiques, cafés and restaurants.

The Seabourn Experience

Aboard the intimate Seabourn Quest, guests will enjoy ocean-front suites, most with a private veranda, intuitive personalized service, world-class dining and Seabourn Conversations, the line's enrichment program featuring engaging presentations and informal discussions by leading thinkers, cultural voices and subject-matter experts. The smaller scale of the ship allows access to boutique destinations and creates a more immersive connection with the places visited throughout the journey. Guests will also sail aboard a refreshed Seabourn Quest, following one of the most comprehensive interior updates in the ship's history. Enhancements across suites, public spaces, dining venues and wellness areas further elevate the comfort, understated luxury and personalized service that define Seabourn.

For more details about Seabourn, call 1-800-929-9391, visit www.seabourn.com or contact a professional travel advisor.

About Seabourn:

Seabourn represents the pinnacle of luxury ocean and expedition travel and operates a fleet of five modern ships. The all-inclusive, boutique ships offer all-suite accommodations with ocean-front views; award-winning dining; complimentary premium spirits and fine wines available at all times; renowned service provided by an industry-leading crew; a relaxed, sociable atmosphere that makes guests feel at home; a pedigree in expedition travel through the Ventures by Seabourn® program and two luxury purpose-built expedition ships, including Seabourn Venture that launched in 2022 and Seabourn Pursuit in 2023. Seabourn takes travelers to every continent on the globe, visiting more than 400 ports including marquee cities and lesser-known ports and hideaways. Guests of Seabourn experience extraordinary offerings and programs, including partnerships with leading entertainers, dining, personal health and wellbeing, and engaging speakers. 

Seabourn is part of Carnival Corporation, the world's largest cruise company with a portfolio of cruise lines operating in over 800 ports & destinations worldwide. (NYSE: CCL).

Find Seabourn on X, Facebook, Instagram, YouTube and Pinterest.

SOURCE Seabourn

Share this article

Prescription-strength combination of acetaminophen and ibuprofen offers non-opioid treatment option and easier access for patients with mild-to-moderate acute pain

AUCKLAND, New Zealand, Sept. 8, 2026 /PRNewswire/ -- Today, AFT Pharmaceuticals announced the U.S. launch of Combogesic®, a new FDA Approved, Non-Opioid, prescription-strength combination of acetaminophen and ibuprofen developed for adult patients (over age 18) for the short-term management of mild-to-moderate acute pain. This adds the US to 66 countries around the world where this product is now available.

In partnership with the Mark Cuban Cost Plus Marketplace, Combogesic brings together two of the world's most well-known pain relievers. Combogesic offers a clinically proven, FDA approved combination, providing healthcare professionals with another non-opioid treatment option for appropriate patients. For one of healthcare's most common experiences, pain management can still involve unnecessary complexity.

Utilizing AFT Pharmaceuticals' Qiksolv® formulation technology, Combogesic combines prescription-strength acetaminophen and ibuprofen into a single tablet. Rather than requiring patients to coordinate multiple medicines and dosing schedules, Combogesic delivers both analgesics in one treatment. Clinical studies have demonstrated the effectiveness of Combogesic in the short-term management of mild-to-moderate acute pain.

"Expectations for pain management have evolved, yet the options to treat have remained limited," said Hartley Atkinson, founder and managing director of AFT Pharmaceuticals. "Rather than inventing another molecule, we asked whether we could rethink how two of the world's most well-known pain medicines could work together in a single prescription-strength product. The result is a proven formulation that gives healthcare professionals another non-opioid treatment option for appropriate patients."

That philosophy extends beyond the medicine itself. Through their partnership with the Mark Cuban Cost Plus Marketplace", AFT Pharmaceuticals is pairing pharmaceutical innovation with a world class pharmaceutical distribution model intended to improve patient health and making Combogesic accessible and affordable to patients across the United States.

"We should all get excited to have more prescription, non-opioid options to combat pain" said Mark Cuban, founder of Mark Cuban Cost Plus Drug Company. "We started Mark Cuban Cost Plus Marketplace because every American should have access to safe, affordable medicines as an essential part of advancing healthcare. So ultimately patients benefit when new medications are paired with access and price transparency. That's exactly what this partnership is about. We're proud to help make Combogesic available to patients across the country."

As pain management continues to evolve, healthcare professionals and patients are looking for treatment options that reflect the realities of modern care. Combogesic reflects AFT Pharmaceuticals' commitment to expanding non-opioid treatment options for appropriate patients.

For more information, visit Combogesic.com.

IMPORTANT SAFETY INFORMATION

See full prescribing information for complete boxed warning.

About AFT Pharmaceuticals

AFT is a growing New Zealand-based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories, which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. Our business model is to develop and in-license products for our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-license our products to licensees and distributors in over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com

About Mark Cuban Cost Plus Drugs

The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells. The costplusdrugs.com online pharmacy launched in January 2022 now carries over 2,300 prescription products, delivered by mail to thousands of happy customers every day. Customers can also go to participating retail pharmacies to receive Cost Plus Drugs pricing through the Team Cuban Card. Cost Plus Drugs is working with health plans, managed-care organizations, PBMs, and self-insured employers to bring these same savings to benefit plans nationwide. Learn more at www.markcubancostplusdrugcompany.com.

IMPORTANT SAFETY INFORMATION Continued…

Contraindications

- patients with known hypersensitivity to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product

- patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.

- Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.

- the setting of coronary artery bypass graft (CABG) surgery.

Warnings and Precautions

- Hepatotoxicity. COMBOGESIC® contains acetaminophen and ibuprofen. Acetaminophen has been associated with cases of acute liver failure; the risk is higher in those with underlying liver disease and in those who ingest alcohol. Use in patients with hepatic impairment is not recommended. Elevations of ALT or AST have been reported in NSAID-treated patients.

- Cardiovascular Thrombotic Events. To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible.

- Gastrointestinal Bleeding, Ulceration, and Perforation. NSAIDs may cause serious and sometimes fatal GI adverse events at any time and without warning. Avoid use in patients at higher risk. In concomitant use with low-dose aspirin, monitor patients more closely for evidence of GI bleeding.

- Hypertension. NSAIDs can lead to onset of new hypertension or worsening of pre-existing hypertension, which may contribute to the increased incidence of CV events.

- Heart Failure and Edema. Avoid use in patients with severe heart failure unless benefits outweigh risk.

- Renal Toxicity and Hyperkalemia. Use in patients with renal impairment is not recommended. Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Increases in serum potassium concentration, including hyperkalemia, have been reported.

- Hypersensitivity and Anaphylactic Reactions. Hypersensitivity and anaphylaxis associated with ibuprofen and acetaminophen have been reported, including life-threatening anaphylaxis associated with acetaminophen.

- Exacerbation of Asthma Related to Aspirin Sensitivity. Patients with asthma may have intolerance to aspirin and other NSAIDs.

- Serious Skin Reactions. Acetaminophen or NSAIDs may cause serious skin reactions such as exfoliative dermatitis, acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), or fixed drug eruption (FDE), generalized bullous fixed drug eruption (GBFDE), which can be fatal and may occur without warning. Discontinue the use of COMBOGESIC® at the first appearance of skin rash or any other sign of hypersensitivity.

- Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). DRESS that may be life-threatening or fatal has been reported in patients taking NSAIDs.

- Fetal Toxicity: Premature Closure of Fetal Ductus Arteriosus. Avoid use of COMBOGESIC® in pregnant women at about 30 weeks gestation and later. COMBOGESIC® increases the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

- Oligohydramnios/Neonatal Renal Impairment. Use of COMBOGESIC® at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment.

- Hematologic Toxicity. Anemia has occurred in NSAID-treated patients and NSAID-treatment may increase the risk of bleeding events.

- Ophthalmological Effects. Blurred or diminished vision, scotomata, and/or changes in color vision have been reported with oral ibuprofen.

- Aseptic Meningitis. Aseptic meningitis with fever and coma has been observed in patients on oral ibuprofen.

- Masking of Inflammation and Fever. Activity of COMBOGESIC® in reducing inflammation, and possibly fever, may diminish signs of infections.

- Laboratory Monitoring. Monitor patients on long-term NSAID treatment with a CBC and a chemistry profile periodically.

Adverse Reactions

The most common adverse reactions (> 2%) are nausea, vomiting, headache, dizziness, somnolence, post-procedural hemorrhage, and swelling of the face.

Drug Interactions

- Drugs That Interfere with Hemostasis. Ibuprofen and anticoagulants have a synergistic effect on bleeding. Concomitant use increases the risk of serious bleeding. Concomitant use of drugs that interfere with serotonin reuptake and an NSAID may increase the risk of bleeding.

- ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers. NSAIDs may diminish the antihypertensive effect of ACE inhibitors, ARBs, or Beta-Blockers. In the elderly, volume depleted, or those that have renal impairment, concomitant use with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure.

- Diuretics. NSAIDs can reduce the natriuretic effect of loop diuretics and thiazides in some patients.

- Digoxin. Concomitant use of ibuprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.

- Lithium.